Back to top
more

SPDR S&P Biotech ETF: (XBI)

(Real Time Quote from BATS) As of May 25, 2018 03:57 PM ET

 Add to portfolio

$92.98 USD

92.98
2,715,920

+0.29 (0.31%)

Volume: 2,715,920

Zacks ETF Rank 2 - Buy   2      

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

ETF Quote Details

Previous Close 92.73
Open 92.86
Bid 92.80
Ask 93.00
Day Low-High 92.36-93.41
52wk Low-High 66.66-97.98
Volume 2,715,920
NAV (month end) 86.90
Premium (+)/Discount (-) (month end)+5.83

Zacks Premium Research for XBI

Zacks ETF Rank Buy 2
ETF Risk High
ETF Research Report

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

ETF Expense Ratio

Expense Ratio 0.35%
Dividend (Yield) $0.24 (0.26%)
Issuer STATE STREET GLOBAL ADVISORS

Benchmark for XBI

S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX

The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.

Fund Summary for XBI

SPDR S&P BIOTECH ETF

The iShares Core S&P 500 ETF Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of U.S. large-cap stocks.